ACLARION, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
ACLARION, INC. (ACON) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $513.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2026-03-18
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $513.00K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $532.00K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $479.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits |
|---|---|
| 2025-12-31 | $513.00K 10-K · filed 2026-03-18 |
| 2024-12-31 | $532.00K 10-K · filed 2026-03-18 |
| 2023-12-31 | $479.00K 10-K · filed 2025-04-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |